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BIOMEDICAL INNOVATION: THE CHALLENGE AND THE PROCESS
As a nation, we have not, to date, established a comprehensive stra-
tegy for understanding and guiding the origins, development, transfer, and
dissemination of medical technologies and practices. Recently, attention
has been focused on the validation of medical practices and the assessment
of the costs and benefits associated with their use. While attention to
these particular aspects of problems facing health technology is
encouraging, it is discouraging that most of the evaluative research
has been limited to the later stages of the innovation process, when the
technology is already being transfered into widescale use,
Since the second world war, the biomedical field has simultaneously
experienced an information explosion and remarkable technical advances in
the detection, diagnosis, therapy, rehabilitation, and prevention of
disease. These advances are broadly referred to as biomedical "technology."
Today, highly sophisticated technology is available for some medical
problems; but, for other problems technology is either inadequate or
non-existent. Advances such as the evolution of sulfa antibiotics may
be a model of the appropriate adoption, utilization, and displacement
of a biomedical innovation over a relatively short time period.*
A new era of medicine and specifically pharmocologic therapy for bacterial
infections began to evolve in 1932 when Gerhard Domagk discovered that
prontosil rubrum, a red dye, protects animals from streptococcal infections.
After three years of exhaustive animal studies and clinical trials, he
made this important discovery public. In 1936, French researchers found
that the bacteriostatic component of the dye was actually sulfanilamide.
English physicians then published reports of positive therapeutic
results with the drugs Prontosil and sulfanilamide in patients with
meningococcal infections, and the use of sulfanilamides spread rapidly.
Their success was reflected in a dramatic decline in morbidity and
mortality from bacterial infections. Meanwhile, penicillin, first discovered
in 1929 was being tested during the early 1940s. Penicillin was so
efficacious that it soon became an indispensible therapeutic agent, and
the use of sulfanilamide began to decline. Although sulfanilamides and other
sulfa drugs are still available, penicillin and many new families of
antimicrobial drugs today have displaced sulfa for treatment of most
infectious diseases,
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Unfortunately, the development and dissemination of medical innovation does
not always occur in such a optimal fashion. Some efficacious medical
practices have been adopted too slowly; some practices have been displaced
too slowly; and others, though clinically valuable, have been too costly.
Such problems are a disservice to the public in need of responsive health
care regimens. Therefore, a high priority for policy development must be
to make the management and conduct of our biomedical research and
development system maximally responsive to the health care needs of the
population.
Appearing before the Senate Subcommittee on Health and Scientific
Research in 1978, Dr. Julius Richmond, then Assistant Secretary for
Health, expressed the Administration's perspective on the need for a policy
on the dissemination of biomedical technology. He noted that:
..... while the Department (DHEW) is extensively involved with
technology as a developer, an evaluator, a purchaser, and a
regulator, it has no comprehensive strategy to link, systema-
tically, stages in the life cycle of technology development,
evaluation, transfer, diffusion, utilization, and phaseout. (1)
A similar view was presented by Representative Henry A. Waxman at a hearing
on the establishment of the National Center for Health Care Technology:
We must find ways to reduce the time it takes to transfer medical
discoveries into daily practice once we know they will improve
patient care. We must prevent premature use of technology which
may have unproven value, and which may trigger long-term side
effects in the patient. (2)
THE CHALLENGE
In the 1980s a major challenge for those who manage biomedical
research will continue to be the guidance of the research and development
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systems so as to produce technology responsive to health care needs. To
respond to that challenge, those who make desicions about the funding
and management of the biomedical innovation process might benefit from a
more complete understanding of the process itself and of its components.
Conceptual Model
At this time, any description of the process of biomedical innovation
must be considered highly theoretical because definitive empirical data
simply to not exist. How, then, do we address ourselves to the objective
of better understanding the process? We propose a conceptual approach to
describe the process, but we present it as a hypothetical model which
must itself be time-tested for validity. The model presents a framework
constructed on theoretical and empirical research from fields outside
the biomedical area. We do not know whether the findings from other fields
are transferable to the iomedical field, but this model is presented
as a useful instrument for organizing a discussion of the effectiveness
of the biomedical research and development system and for initating
future research directions.
We identify two components in our model of innovation. The first
component is the progression of technology from ideas to products, that
is, health care devices, drugs and practices. The second component
consists of the interactions among people that bring these ideas to
fruition. These two components are highly interrelated but distinct.
The overall flow of innovation is through four distinct stages.
The first is the generation of ideas in basic, clinical, and applied
research. These deas are prompted by the goal to more fully understand
Originally proposed at the Conference on Development and Dissemination
of Biomedical Innovation sponsored by the National Heart, Lung, and
Blood Institute and the Office of Medical Applications of Research, NIH.
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life processes and the causes and cures of disease. The second stage is
communication of ideas. Researchers must communicate ideas among themselves
to integrate the essential pieces of knowledge that will eventually be
developed into a specific technology. At the third stage, development of
clinical applications, researchers and technologists respond to societal
needs with practical applications of ideas for the diagnosis and treatment
of disease. In private industry, the economics of the marketplace are
highly influential on the directions of research applications. During
the fourth stage the packaged technology or medical practice becomes
a market good that moves out of the research community toward adoption
or diffusion in society.
Linking the four stages and spurring or deterring the progress of an
innovation is evaluation. In one sense, evaluation is integral to each
stage of the innovation process because at all stages of research some
component of evaluation is built into a research design. It is the nature
of the scientific method to test and of the peer-review system in the
biomedical research community to evaluate. Formalized evaluation and
validation, however, in the form of clinical trials or other validation
research, often occurs at the third stage, clinical applications, before
a technology is disseminated for adoption. Existing technology is contin-
ually evaluated and re-evaluated by practitioners and patients and, in
some cases, regulatory and research agencies of the federal government.
Evaluation identifies needs, successes, and failures that can be fed
back into any of the previous stages of the process. This feedback
maintains the dynamics of the system, forcing the improvement of
technology and motivating the search for more detailed knowledge of
health and disease. Figure 1 is a diagram of the biomedical research
spectrum that depicts its program planning concepts. The top arrow
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identifies the first four stages of the model, the middle arrow specifies
the categories of research currently funded to advance the biomedical
research continuum, and the third arrow states the primary objectives
of each phase of the research continuum.
Several conceptual questions are apparent in our theoretical model.
The first question is how to structure and characterize the flow of
skills and personnel as integral and transitional to each stage of the
model. The health care industry, from the generation of ideas to the
evaluation of health care technology, may be different from other
industries in its use of research skills. In at least one subset of
the biomedical researchers there is a close relationship between the
idea generators and those who put the technology into practice, namely
physicians. In industries related to consumer goods, such as the auto-
mobile and electronics industries, researchers come from diverse basic
disciplines such as chemistry and metallurgy. These researchers
certaintly use the ultimate products of their research but cannot
be considered to promote or prescribe them in the marketplace.
In the health sector, however, practitioners often enjoy the opportunity
of a close relationship with researchers. The majority of biomedical
research in the United States takes place in universities which combine
research settings with practice settings. A clinical researcher might
have an office next door to a physiologist and not far away might be a
cardiac disease clinic. Interacting with both individuals are medical
students who provide. erhaps. the fastest link to practice. Of course,
other subsets of researchers are not as close to clinical practice, for
example. device manufacturers and the harmaceutical industry. Neither
are the federal government's health policy, regulatory, and other related
_________________________ 
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agencies close to clinical practice; yet, to do their work, they must
reach out and involve clinicians in their program and policy development
and decision-making. While this conceptual view of technology development
is appealing with its double stream of ideas and skills, we have little
research to indicate whether this view is useful or valid. Some
evidence does exist however about the nature of the flow of ideas and
the relationship between this flow and health care skills and personnel.
A study by Comroe and Dripps which characterizes major advances in the fields
of cardiovascular and pulmonary medicine has shown that research
advancement relies on bringing together disparate pieces of information
and various skills at the right time in the right setting. (3)
The second question is how to identify those factors within the flow
of innovations that determine whether an innovation skips a stage, is
unduly detained at a stage, or never proceeds beyond a certain stage.
We do know, for instance, that considerable lag time has existed between
discoveries and their eventual validation and application. We do not
know why. Whether lag time exists today is essentially unanswerable now
and can be determined only retrospectively, but it is a concern we must
continually explore. We also know that some innovations have been adopted
too early and have had a negative impact on society. In our greatly
increased capacity to communicate through the literature and electronic
media is the potential for over-rapid communication or over-rapid
development and adoption of technology before it is appropriately or
adequately evaluated. At the same time, we must recognize that validation
is an exceedingly expensive procedure and that our financial and manpower
resources are finite.
-The succeeding section of this article gives the background, rationale,
and proposed future research directions for each of the four stages of
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of the biomedical innovation model. We do not consider the proposed
research directions definitive or complete. We suggest that the
challenge is to translate these ideas into a coherent research framework,
one that we in the biomedical community can use to continue, if not
accelerate, the major improvements in health status witnessed during the
past eight decades.
THE PROCESS: RESEARCH BASE AND FUTURE DIRECTIONS
Meeting the challenge of guiding research and development systems
to produce technology responsive to health care needs involves exploring
new approaches. In understanding the stages of technology development
in health, we can best benefit from previous research in other fields by
carefully examining health-related patterns rather than quickly accepting
the applicability of those findings to the health field. Several specific
differences seem to justify this caution: 1. Greater uncertainties are
involved in natural science research and development than in the physical
sciences, including issues of biomedical variability and efficacy deter-
mination; 2. The federal government sponsors much biomedical research but,
unlike defense, is not the direct customer for the products of that
research.; 3. Among scientific and technical fields, biomedical research has
a high degree of academic dominance; 4. Biomedical technology has a high
degree of government regulation of product acceptability and diffusion;
and; 5,. The market for biomedical technology usually involves the
responses by medical practitioners as intermediaries and only then the
public as the ultimate consumers with health care needs.
To construct a framework for considering these cautions and new
approaches, we overview in this section the existing research bases and
proposed future directions for the successive, interrelated communication
of ideas and knowledge, development of clinical applications, and
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diffusion and adoption of technology, and for the multi-stage process of
evaluation of medical technology.
Stage One: Generation of Ideas
The generation of ideas, the first stage in the biomedical innovation
process, begins with the decision to pursue one line of research instead
of another and is influenced by characteristics of the ideas themselves,
the innovators, the research organizations, and forces external to the
organizations and science.
Research Base. The bulk of research on the generation of ideas has
related to the creativity of individual researchers--how they arrive at
new ideas and follow through to innovation. In the late 1950s,
attention turned to the innovation process in industrial and governmental
research and development (R&D) organizations. The basic assumption
behind this research was that the quantity and quality of work performed
by scientists and engineers are affected by the organizational settings
in which they work. A research goal was to explore how the organizational
setting influences the researcher's utilization of basic talents; a policy
goal was to find ways to enhance desired types of scientific performance
by modifying organizational factors. Most of the research was done in
industrial settings and little in the biomedical area,
Pelz and Andrews (4) and Andrews with other colleagues (5) studied
the effects of various organizational and individual factors on technical
performance by 11,200 members of RD groups in the U.S. and six European
countries in universities, medical schools, government laboratories,
and industrial settings. Their research identified a number of
factors which had a significant positive correlation with scientific
performance: diversity of professional activities, the age of the
research group, the quality of research planning, and the skills of
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supervisors. The correlations, however, do not resolve the issue of
causality. It is still uncertain, for example, whether diversity of
function is a factor that contributes to higher performance or whether
high performance is responsible in part for the diversity.
A small interview survey of SO academic physicians reported by Finkelstein
and colleagues is more specific to the issue of research productivity in
the medical community. C6) Here the findings on how diversity contributes
to performance were interpreted to be a limited corroboration of the
Pelz and Andrews work. In health research, productivity also relies, we
believe, on an adequate pool of physician-researchers. To determine the
characteristics of medical students that indicate a strong potential
to become physician-researcher, the Association of American Medical Colleges
has been conducting a longitudinal study of the class of 1960 at 28 U.S.
medical schools. Findings from this study show that a combination of high
ability, aesthetic and theoretical values, and a preference in college for
the humanities and mathematics indicates strong potential to become a
physician-researcher. C7) Two measures are correlated with the quality
of innovative ideas: the success of a first grant application and post-
doctoral training of M.D.s and Ph.D.s, particularly at major research centers.
Future Directions. The following important questions about the genera-
tion of ideas in the biomedical setting need research study. What is the
relative role of universities, medical schools, government laboratories,
and small and large companies in generating ideas? Are processes for
generating radical breakthroughs in medicine similar to or different from
those for generating incremental improvements? Do successful and unsuccessful
clinical investigation, diagnostic and therapeutic techniques, and drugs
arise in the same way or in different ways? Can a better understanding of
idea generation lead to developing technology that improves the productivity
__I___IPCm__*_I______ 
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of the health care system and reduces its costs? These and other questions
should be approached systematically, perhaps beginning with a comprehensive
description of the conditions under which biomedical research is currently
done and an exploration of methodologic strategies for measuring research
productivity in medical settings.
Stage Two: Communication of Ideas and Knowledge
Communication of ideas and data among researchers has, no doubt,
various motivations, including the desires to advance a discipline, to
enhance professional stature, to adhere to the established scientific
practices, and to potentiate further idea development. The communication
of ideas and technical knowledge occurs through a myriad of channels
among and between basic and clinical researchers, technical developers,
practitioners, hardware entrepreneurs, and drug manufacturers. Formal
channels, such as publication in scientific journals and presentations at
scientific meetings, are distinct from the less formal ways in which
scientists and engineers exchange information.
Research Base. Early research in this area has been largely outside
of fields related to medicine and has been aimed at better understanding
the patterns of technical communication. This work has been based on the
assumption that timely and effective communication of information among
researchers can significantly enhance research productivity.
In comparing the patterns of communication of research scientists
and research engineers, Allen found that formal documentation, books,
journals, and reports were not important communication channels of
innovative ideas for engineers in industrial settings. (8) Research
scientists, however, relied heavily on these formal channels. Allen
attributes the difference in patterns to the difference between science
and technology: science is universal and scientists can effectively
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communicate with others throughout the world, whereas technology is local
with its goals defined in terms of local cultures and interests as perceived
by a specific organization. Although the nature of technology generally
renders communication outside the organization difficult, a subset of
researchers do actively take the lead in communicating with the outside
world. These technological gatekeepers appear to be the most effective
means for informally bringing technology into and out of technology-oriented
organizations.
Can these findings about communication patterns among scientists and
engineers be applied to the biomedical research field? The organizational
patterns of academic medicine may be different from than those of industrial
settings. The fact that the academicians' recognition system is nationally
linked to their disciplines or specialities may foster a special set of
communication patterns. Thus, the communication habits of engineers may not
match or be transferable to those of biomedical researchers. However, there
may be less of a differences in patterns of communication among scientists
and biomedical researchers in technological innovation where the boundary
between the generation and application of new scientific knowledge is less
distinct.
Basic and clinical researchers in medicine read the biomedical
literature, but a paucity of data specifies the effects of that reading.
One approach to enhancing communication among biomedical researchers is
currently being attempted by the National Library of Medicine CNLM). C9)
Because publications accumulate at such a rapid rate, NLM is studying how
to connect researchers quickly and efficiently with proper information
channels. NLM has set up a data base of reviewed literature about viral
hepatitis. An intermediary group of experts distills the mass of information
on hepatitis to a manageable size and system. It is estimated that 70-100
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such data bases would provide a fairly comprehensive coverage of (a) diseases
of high morbidity and high mortality requring frequent physician-patient
interaction; (b) diseases causing high expenditures, and; (c) of diseases
about which information changes rapidly. However, we still lack measures
of the likely effects of these data bases on researchers' productivity.
Future Directions. The important research questions about communication
of ideas and knowledge in the biomedical field deal with the patterns and
alternatives of communication. What, specifically, are the communication
patterns among basic and clinical researchers? What channels do they predom-
inantly use for communicating ideas? To what extent do they use alternative
channels? How can the communication process be improved and fostered?
The same questions should be asked about communication between researchers
and practicing physicians. Also, the applicability of models developed
outside the biomedical research sphere should be questioned because of the
possibly unique characteristics of the sciences, scientists, and
practitioners in biomedical research.
Stage Three: Clinical Applications and Development
Only a fraction of the knowledge generated from biomedical research
is selected for the development of applications in the clinical setting.
The procedure for selecting future developments involves a number of factors,
including need, efficacy, cost, and profit. Transforming that research
knowledge into applied clinical technology involves the cooperative partici-
pation of the research and health practice communities, the public,
industry, and the government.
Research Base. Studies within and outside the health field have
addressed the issue of the advisability of supporting targeted basic or
applied research to produce technology with high social impact. The
approach typically adopted in these studies has been retrospective,
III
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tracing major advances back to their origins. The ideal approach would
probably be to follow a number of basic research ideas prospectively
through the stages leading to widespread use. However, prospective
studies are impractical because research ideas historically have a high
mortality, as has been documented in the literature of industrial management.
Among the earliest studies of this type was Project Hindsight, commis-
sioned by the U.S. Department of Defense and reported in 1966. C10) A
team of scientists and engineers analyzed retrospectively how 20 important
military weapons came to be developed. Two conclusions were that the
contributions of research and development in the nonprofit sector,
particularly universities, were no greater proportionately than in other
sectors, and that scientists and engineers contributed most effectively when
the effort was mission-oriented. Many other studies of industrial innovation
support the importance of market or need-pull as an initiating factor for
successful development.
Subsequently, some studies of research outcomes in the medical, physical,
and social sciences arrived at conclusions contrary to those of Project
Hindsight. The study of Conroe and Dripps C3) was devoted entirely to
innovations in cardiovascular and pulmonary medicine occurring from
1945-1975. The conclusion in which these investigators had the highest
confidence was that a diversity of clinical and basic research, including
all types of early innovative process activity, was important in the
development of ten most important cardiopulmonary clinical advances. They
could not identify a single type of early innovative activity whose
productivity overshadowed all other types.
As in studying the generation of ideas, determining the environmental
factors that contribute to the individual's and organization's performance
is a useful approach to understanding development of clinical applications.
WFBI  ____
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In interviews with 66 faculty members in engineering and science departments
at a leading technological university, Roberts and Peters explored the
demographic and environmental characteristics of researchers who had
ideas for applied technology as well as the characteristics of those who
also attempted to transfer their technologies into use. (11) The
following characteristics distinguished the idea exploiting faculty from
others: being a first-born son; writing a book; obtaining a patent;
being aware of potential financial support. (12)
In successful commercially oriented development, Roberts and Fusfeld
argue that several staff roles are key: idea generators; idea exploiters
or entrepreneurs; gatekeepers, or linking communicators, who bring ideas
into the organization; program managers, and; sponsors or coaches. C13)
Roberts has also assembled evidence that indicates commercial development
appears to be most successful when it is strongly tied to market needs
or demands. Frequently, innovative users of products implement their
own solutions to needs, and subsequently manufacturers adapt them for more
widespread production. New companies are especially prolific in product
innovation. (14).
Future Directions. Knowledge about these aspects of commercial
innovation point out the gaps of knowledge in the biomedical area. Do
these findings apply to health and biomedical innovation? Innovations
in drugs, devices, and clinical practices might well be subject to
different or similar factors; however, systematic empirical studies rather
than anecodotal group experience and speculation should be conducted to
and compare the development processes relevant to medical practices and
products. A particular focus for the retrospective study of the development
of selected health technologies might be the factors that influenced the
process after the scientific base was clearly established. Another focus
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might be the structural linkages related to successful biomedical
development, for example, the mechanisms of the idea transfer from universi-
ties to industry, with special emphasis on the role of academic medical
centers; the role of new company formation in transferring biomedical know-
ledge into use; the relationships between pharmaceutical research
laboratories and their own commercial development activities. A further
focus might be on the various incentives for development, including the
role of regulatory standards for efficacy and safety, the availability
of capital for development, and the role of third-party payers. Once
data from such studies are available, useful managerial and government
policy implications can potentially be derived.
Stage Four: Diffusion and Adoption of Technology
Once new technologies have been developed and initially applied to
health care and health delivery systems, information about their usefulness
needs to be made available to prospective users. Formal and informal
dissemination channels exist and may be operational. The decision by
prospective users to adopt or not to adopt a new technology may relate
to both characteristics of the technology and characteristics of the
users. In addition, evaluative information, continuing medical education,
and media publicity may affect patterns of adoption. The dissemination
process is the stage that has received the greatest research attention
within the biomedical field. C15)
Research Base. Research on the process of information dissemination
has well established the existence of several aspects of the process. C16)
The classic model of diffusion recognizes the gatekeeper or near-peer as
the primary determinant of diffusion of commercial ideas. The hierarchical
structure of an institution or an organization also influences technology
diffusion. A clear distinction has been made between the initial
I-
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adoption process of a new technology and its acceptance or even eventual
institutionalization. The trend of adoption and decay has been described
as an S-shaped curve for some technologies but may not be universally
applicable. It is not known, for example, whether equipment-embodied
goods and software diffuse differently. Re-invention, or adaptation of
technology to local circumstances, has been recognized, as has the fact
that adoption does not necessarily imply proper use. (17) Finally, the
role of a marketing component, such as advertising, has been studied. (18)
A classic study of innovation dissemination conducted in the biomedical
field is assumed to have general applicability. Coleman, Katz and Menzel
examined the patterns of adoption of a new antibiotic by physicians
practicing in three small communities. (19) They determined that the
information was most effectively disseminated through informal communica-
tion networks among physicians within each community. The informal channels
were more effective than the formal channels of journal reports, scientific
meetings, and drug promotional activity. The Office of Technology
Assessment of the U.S. Congress is said to have reviewed numerous studies
of the diffusion and adoption of medical technologies and concluded that
among the most important factors determining whether and how rapidly
a physician will adopt a new technology are his or her own clinical
experience and that of colleagues.
A few studies have examined behavioral change by health practitioners
and the public, for example, Finkelstein and colleagues examined the
change in use of certain drug therapies as a function of clinical
validation efforts. (20) Other sources of information such as advertising
campaigns, technical literature, and programs of continuing education can
have an important secondary impact on health-related behavior. Farquhar
and colleagues, in their three-community study of the dissemination of
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individual health behavior information for the prevention of cardiovascular
disease, suggest that it is possible to alter an individual's health
behaviors by a mass media campaign alone or in concert with other educational
strategies. (21) Data from the NIH-sponsored National High Blood Pressure
Education Program whose objective is to disseminate high blood pressure
information to practitioner and patient alike suggest that in 1971 only 50
percent of the millions of Americans known to have high blood pressure were
aware of their condition. By 1974, this figure had risen to 70 percent
as health providers began to develop the skills needed to effectively
communicate health information. Similarly, only 4 million of those
hypertensive Americans were under adequate control in 1971; by 1974, that
figure had apparently doubled. In addition, there has been a very marked
increase in the number of total patient visits to physicians for
hypertension and hypertensive heart disease, while total patient visits
for all causes have increased only slightly. C22)
Other work in the medical field has attempted to identify the
characteristics of the innovation process that favor the adoption of
technological innovation by hospitals. Gordon and colleagues considered
the importance of organizational factors affecting the adoption of
technology by hospitals. (15) Russell has demonstrated that the S-shaped
curve is applicable to the adoption by hospitals of some of the most
costly technologies. C23)
Future Directions. More study is needed of the factors that encourage
or impede the diffusion of clinically validated drugs, devices, and
techniques to th$ practice community. How do medical practitioners
presently learn about new drugs, diagnostic tools, and advances in
clinical practice? How, for example, do the characteristics of the
technology and the health care environment of potential users affect the
cl ..
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dissemination of ideas and practices? Are peer relationships the primary
determinant of diffusion of clinical practices? What is the nature of
peer relationships in diffusion? How important are organizational
factors and marketing approaches? What are the relative roles of formal
and informal diffusion channels? What is the impact of political, economic,
social, and ethical factors on the public and on the health care professional's
behavior?
Evaluation of Medical Practices
Growing public concern about the adequacy of health care and health
costs and the ever faster pace of biomedical research have made evident;
the complex nature of the entire process of biomedical innovation. Evaluation
of medical practices, which does not and should not necessarily occur at the
end of the innovation process, encompasses those activities which determine
the safety and efficacy of the practices and their social impact. It may
serve as a predictor of the success of a technology. Evaluation may provide
feedback that influences other aspects of the process, for example, the
extent of dissemination of a medical practice or the decision by a
commercial developer whether to select a technology for later marketing.
Research Base. A number of researchers and several government agencies
are taking the lead in evaluating the safety, efficacy, and social
impact of health technology on medical practice. Considerable work has been
reported on the experimental methodologies for conducting clinical validation
studies. (24) Others have written about efforts to rationalize clinical
decision-making as to the choice of specific therapies or diagnostic
tests for patients. (25) The case for evaluating medical practices has
most often been based upon the increasing costs of health care delivery
and the scarcity of societal resources that can be expended on human
services. (26,27,28) Researchers have responded with reports of
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cost/benefit analyses or cost/effectiveness studies of particular
practices or programs which were of interest. C29) At least one
author has recently called for evaluating not only technology, but also
the research process that leads to it. (30)
Efforts by government agencies have included the major study of the
cost-effectiveness of a large number of health technologies that have
been undertaken by the Office of Technology Assessment. OTA staff were
among the first to publicly recognize the importance of dealing
systematically with problems associated with the use -of medical technology.
The Institutes of the National Institutes of Health and its Office for
Medical Applications of Research have embarked on a program of "Consensus
Development" designed to resolve controversy and uncertainty in the use of
certain medical practices. Conferences of experts are convened, followed
by the dissemination of their consensus opinion about a use or practice.
An important activity undertaken by the National Center for Health Care
Technology, in cooperation with other health agencies is the attempted
development of means to evaluate emerging medical practices before they
are widely disseminated. Products of this work, if successful, could
lead to models for predicting whether emerging technologies will have
a significant effect on the health status of the population or whether
their potential will ever by fully realized.
Future Directions. Evaluating the efficacy of the products of research
is very expensive. Typical clinical trials cost on the average of $1,000 to
$2,000 per patient per year; some clinical trials for cardiovascular
disease therapies involve thousands of patients and hundreds of investi-
gators and cost as much as $100,000,000. With such extensive research
required it seems that alternative means must be found for validation,
such as data from registries, data from physician practice, or the use of
_ ___. 1 14( _1
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retrospective data. While none of these alternatives compares with the
randomized controlled clinical trial in precision of results, these or
similar alternatives can help to provide much needed information on
the efficacy of regimens.
The use of concensus development in formal conferences to assess
the state of knowledge concerning the appropriate use of regimens is
promising, but much remains to be learned about how to manage the
consensus process as well as the validity and the impact of the results.
The effect that evaluation data has on basic research has not been
investigated, although Levy and Sondik note in at least one instance,
blood pressure reduction, that clinical trials that demonstrate the
efficacy of a medical practice have lead to a rebirth of interest and new
knowledge development into the basic causes of the disorder. (31) Clearly,
a relationship should exist between validation and basic research, and
that relationship must be well understood if the research process is to
be as effective as possible.
CONCLUSION
With health care costs in the United States along nearly $400 billion
annually and with. a federal biomedical research budget of only $4 billion,
we have every incentive to make the best use of our resources and to
learn how to guide appropriate scientific developments to follow
comparably successful pathways. The process as outlined in our model
is only a tentative first attempt at a description. Knowledge of each
stage in the innovation process is severely limited. The challenge seems
clear: if we are to address the toll of disease most effectively and
efficiently our efforts need to include the establishment of policies
which encourage an understanding of how the biomedical system functions.
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